Tags

Type your tag names separated by a space and hit enter

The changing incidence of in situ and invasive ductal and lobular breast carcinomas: United States, 1999-2004.
Cancer Epidemiol Biomarkers Prev. 2009 Jun; 18(6):1763-9.CE

Abstract

BACKGROUND

National incidence rates for lobular and ductal breast cancers have not been available previously. Evidence suggests that the increased risk of breast cancer associated with combined hormone replacement therapy use is higher for invasive lobular cancers (ILC) than for invasive ductal cancers (IDC). This study provides U.S. incidence rates for these histologic types for both in situ and invasive cancers and assesses changes in the incidence of these cancers over time.

METHODS

Data for this study included incident ductal and lobular breast cancer cases diagnosed from 1999 through 2004 in central cancer registries in 44 states and the District of Columbia from the National Program of Cancer Registries and the Surveillance, Epidemiology, and End Results program. We estimated incidence per 100,000 women by 10-year age groups, race, and ethnicity. We also assessed the percent change in invasive and in situ cancer incidence over time.

RESULTS

We observed distinct differences in the change of incidence over time between in situ and invasive lobular and ductal breast cancers. The age-adjusted rates of ILC and IDC declined an average of 4.6% and 3.3% per year, respectively. Overall, ILC decreased 20.5% from 1999 to 2004. The patterns of ductal and lobular in situ cancer incidence were not consistent over time, and the total change was negligible.

CONCLUSION

The declines in ILC observed in our study are consistent with a decrease in cancer incidence related to a reduced use of combined hormone replacement therapy. However, other factors could also be responsible for these changes.

Authors+Show Affiliations

Cancer Surveillance Branch, Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia 30341-3724, USA. CEheman@CDC.GOVNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

19454615

Citation

Eheman, Christie R., et al. "The Changing Incidence of in Situ and Invasive Ductal and Lobular Breast Carcinomas: United States, 1999-2004." Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored By the American Society of Preventive Oncology, vol. 18, no. 6, 2009, pp. 1763-9.
Eheman CR, Shaw KM, Ryerson AB, et al. The changing incidence of in situ and invasive ductal and lobular breast carcinomas: United States, 1999-2004. Cancer Epidemiol Biomarkers Prev. 2009;18(6):1763-9.
Eheman, C. R., Shaw, K. M., Ryerson, A. B., Miller, J. W., Ajani, U. A., & White, M. C. (2009). The changing incidence of in situ and invasive ductal and lobular breast carcinomas: United States, 1999-2004. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored By the American Society of Preventive Oncology, 18(6), 1763-9. https://doi.org/10.1158/1055-9965.EPI-08-1082
Eheman CR, et al. The Changing Incidence of in Situ and Invasive Ductal and Lobular Breast Carcinomas: United States, 1999-2004. Cancer Epidemiol Biomarkers Prev. 2009;18(6):1763-9. PubMed PMID: 19454615.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The changing incidence of in situ and invasive ductal and lobular breast carcinomas: United States, 1999-2004. AU - Eheman,Christie R, AU - Shaw,Kate M, AU - Ryerson,Aliza Blythe, AU - Miller,Jacqueline W, AU - Ajani,Umed A, AU - White,Mary C, Y1 - 2009/05/19/ PY - 2009/5/21/entrez PY - 2009/5/21/pubmed PY - 2009/9/9/medline SP - 1763 EP - 9 JF - Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology JO - Cancer Epidemiol. Biomarkers Prev. VL - 18 IS - 6 N2 - BACKGROUND: National incidence rates for lobular and ductal breast cancers have not been available previously. Evidence suggests that the increased risk of breast cancer associated with combined hormone replacement therapy use is higher for invasive lobular cancers (ILC) than for invasive ductal cancers (IDC). This study provides U.S. incidence rates for these histologic types for both in situ and invasive cancers and assesses changes in the incidence of these cancers over time. METHODS: Data for this study included incident ductal and lobular breast cancer cases diagnosed from 1999 through 2004 in central cancer registries in 44 states and the District of Columbia from the National Program of Cancer Registries and the Surveillance, Epidemiology, and End Results program. We estimated incidence per 100,000 women by 10-year age groups, race, and ethnicity. We also assessed the percent change in invasive and in situ cancer incidence over time. RESULTS: We observed distinct differences in the change of incidence over time between in situ and invasive lobular and ductal breast cancers. The age-adjusted rates of ILC and IDC declined an average of 4.6% and 3.3% per year, respectively. Overall, ILC decreased 20.5% from 1999 to 2004. The patterns of ductal and lobular in situ cancer incidence were not consistent over time, and the total change was negligible. CONCLUSION: The declines in ILC observed in our study are consistent with a decrease in cancer incidence related to a reduced use of combined hormone replacement therapy. However, other factors could also be responsible for these changes. SN - 1538-7755 UR - https://www.unboundmedicine.com/medline/citation/19454615/The_changing_incidence_of_in_situ_and_invasive_ductal_and_lobular_breast_carcinomas:_United_States_1999_2004_ L2 - http://cebp.aacrjournals.org/cgi/pmidlookup?view=long&pmid=19454615 DB - PRIME DP - Unbound Medicine ER -